Amalgamated Bank Has $6.99 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Amalgamated Bank cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,896 shares of the company’s stock after selling 684 shares during the period. Amalgamated Bank’s holdings in IDEXX Laboratories were worth $6,985,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. FSA Wealth Management LLC acquired a new stake in IDEXX Laboratories in the 3rd quarter worth approximately $25,000. E Fund Management Hong Kong Co. Ltd. raised its holdings in IDEXX Laboratories by 5,700.0% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after acquiring an additional 57 shares during the period. Retirement Wealth Solutions LLC acquired a new position in IDEXX Laboratories during the 4th quarter worth $31,000. Ashton Thomas Securities LLC acquired a new stake in shares of IDEXX Laboratories in the third quarter valued at about $37,000. Finally, Kestra Investment Management LLC acquired a new stake in IDEXX Laboratories in the 4th quarter valued at approximately $38,000. 87.84% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on IDXX shares. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. Barclays upped their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Bank of America lifted their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Piper Sandler upped their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Finally, Morgan Stanley reduced their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $533.75.

Insiders Place Their Bets

In related news, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $457.81 on Thursday. The company has a 50 day moving average of $434.18 and a 200-day moving average of $451.92. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39. The firm has a market cap of $37.23 billion, a price-to-earnings ratio of 42.91, a PEG ratio of 3.41 and a beta of 1.37. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.